Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Fleseriu

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
European Journal of Endocrinology|August 18, 2022
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extensionMaria Fleseriu, John Newell-Price, Rosario Pivonello, et al.
Reviews in Endocrine & Metabolic Disorders|June 11, 2025
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic reviewSabrina Chiloiro, Carmelo Caldarella, Alessandra Vicari, et al.
European Journal of Endocrinology|September 29, 2022
Durable biochemical response and safety with oral octreotide capsules in acromegalySusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
European Journal of Endocrinology|August 3, 2021
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDYMaria Fleseriu, Dagmar Führer-Sakel, Aart J van der Lely, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Lancet. Diabetes & Endocrinology|July 31, 2020
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phaseRosario Pivonello, Maria Fleseriu, John Newell-Price, et al.
Neurosurgery|September 17, 2016
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary AdenomasMateo Ziu, Ian F Dunn, Christopher Hess, et al.
European Journal of Endocrinology|February 20, 2025
Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statementKristina Isand, Hiroshi Arima, Jerome Bertherat, et al.
The Lancet. Diabetes & Endocrinology|December 26, 2021
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trialMaria Fleseriu, Alexander Dreval, Irina Bondar, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2025
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-Daily Oral Paltusotine TreatmentBeverly M K Biller, Alessandra Casagrande, Atanaska Elenkova, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
European Journal of Endocrinology|August 18, 2022
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extensionMaria Fleseriu, John Newell-Price, Rosario Pivonello, et al.
Reviews in Endocrine & Metabolic Disorders|June 11, 2025
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic reviewSabrina Chiloiro, Carmelo Caldarella, Alessandra Vicari, et al.
European Journal of Endocrinology|September 29, 2022
Durable biochemical response and safety with oral octreotide capsules in acromegalySusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
European Journal of Endocrinology|August 3, 2021
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDYMaria Fleseriu, Dagmar Führer-Sakel, Aart J van der Lely, et al.
The Journal of Clinical Endocrinology and Metabolism|September 4, 2020
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideSusan L Samson, Lisa B Nachtigall, Maria Fleseriu, et al.
The Lancet. Diabetes & Endocrinology|July 31, 2020
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phaseRosario Pivonello, Maria Fleseriu, John Newell-Price, et al.
Neurosurgery|September 17, 2016
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary AdenomasMateo Ziu, Ian F Dunn, Christopher Hess, et al.
European Journal of Endocrinology|February 20, 2025
Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statementKristina Isand, Hiroshi Arima, Jerome Bertherat, et al.
The Lancet. Diabetes & Endocrinology|December 26, 2021
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trialMaria Fleseriu, Alexander Dreval, Irina Bondar, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2025
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-Daily Oral Paltusotine TreatmentBeverly M K Biller, Alessandra Casagrande, Atanaska Elenkova, et al.
Pageof 27